POSC NEWS! -Positron Sees Tenfold Increase in Attrius(TM) Quote Proposals
INDIANAPOLIS, May 21, 2010 (BUSINESS WIRE) -- Positron Corporation (OTCBB:POSC)
(the "Company") a molecular imaging solutions company focused on Nuclear
Cardiology, states that over the first 4 months of 2010 that it has seen
tremendous interest in its Attrius(TM) dedicated cardiac PET scanner. The
Attrius(TM) was introduced in the 4th quarter of 2009 and has been met with
critical acclaim throughout the molecular imaging industry.
Patrick G. Rooney, Positron Corporation's CEO states, "The Nuclear Cardiology
industry is experiencing a shift from SPECT to PET as a result of molly
shortages combined with changes in reimbursement. Positron is in an ideal
position to capitalize on this shift more so than any other imaging company. The
Attrius(TM) is a state of the art, Frost & Sullivan New Product Innovation Award
winning, device that was designed to be optimized for Cardiac imaging allowing
physicians an easy transition to PET. Our pipeline for PET systems has had
significant increases each month since we launched the Attrius(TM) late last
year. Our current pipeline has over 55 potential and/or pending sales with the
second half on the year still too follow. We have done a very good job of
positioning Positron to meet this new demand. Based on the current interest we
believe we will meet or exceed our projected system sales moving forward.
Positron's objective is to be the leader in cardiac PET solutions. We believe we
will continue to see substantial growth from both devices and
radiopharmaceuticals."
About Positron: Positron founded in 1983, is a molecular imaging company focused
on Nuclear Cardiology. Positron utilizes its proprietary product line to provide
unique solutions to the Nuclear Medicine community ranging from imaging systems
to radiopharmaceutical distribution. Positron products include: the Attrius(TM),
a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear
Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the
Tech-Assist(TM), a radiopharmaceutical injection shield. Positron is
headquartered in Indianapolis, Indiana. More information about Positron is
available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not guarantees of
future performance and may involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements of
Positron Corporation to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. Our
actual results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in our filings with the Securities
and Exchange Commission.
For further information, please contact Positron Corporation at (317) 576-0183.
SOURCE: Positron Corporation
CONTACT:
Positron Corporation
Patrick Rooney, (317) 576-0183
